Erschienen in:
01.05.2014 | Regional Cancer Therapies
Aggressive Locoregional Surgical Therapy for Gastric Peritoneal Carcinomatosis
verfasst von:
Deepa Magge, MD, Mazen Zenati, MD, PhD, Arun Mavanur, MD, Joshua Winer, MD, Lekshmi Ramalingam, MD, Heather Jones, MPA-C, Amer Zureikat, MD, Matthew Holtzman, MD, Kenneth Lee, MD, Steven Ahrendt, MD, James Pingpank, MD, Herbert J. Zeh, MD, David L. Bartlett, MD, Haroon A. Choudry, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 5/2014
Einloggen, um Zugang zu erhalten
Abstract
Background
Peritoneal carcinomatosis from gastric cancer (GPC) responds poorly to systemic chemotherapy. Limited published data demonstrate improved outcomes after aggressive locoregional therapies. We assessed the efficacy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) in GPC.
Methods
We prospectively analyzed 23 patients with GPC undergoing CRS/HIPEC between 2001 and 2010. Kaplan–Meier survival curves and multivariate Cox regression models identified prognostic factors affecting oncologic outcomes.
Results
CRS/HIPEC was performed for synchronous GPC in 20 patients and metachronous GPC in 3 patients. Adequate CRS was achieved in 22 patients (CC-0 = 17; CC-1 = 5) and median peritoneal cancer index was 10.5. Most patients received preoperative chemotherapy (83 %) and total gastrectomy (78 %). Pathology revealed diffuse histology (65 %), signet cells (65 %) and LN involvement (64 %). Major postoperative morbidity occurred in 12 patients, with 1 in-hospital mortality at postoperative day 66. With median follow-up of 52 months, median overall survival (OS) was 9.5 months (95 % confidence interval 4.7–17.3), with 1- and 3- year OS rates of 50 and 18 %. Median progression-free survival (PFS) was 6.8 months (95 % confidence interval 3.9–14.6). In a multivariate Cox regression model, male gender [hazard ratio (HR) 6.3], LN involvement (HR 1.2), residual tumor nodules (HR 2.4), and >2 anastomoses (HR 2.8) were joint significant predictors of poor OS (χ
2 = 18.2, p = 0.001), while signet cells (HR 8.9), anastomoses >2 (HR 5.5), and male gender (HR 2.4) were joint significant predictors of poor progression (χ
2 = 16.3, p = 0.001).
Conclusions
Aggressive CRS/HIPEC for GPC may confer a survival benefit in select patients with limited lymph node involvement and completely resectable disease requiring less extensive visceral resections.